Viridian Therapeutics plans to initiate an immediate rollout of the treatment, with physicians authorized to begin writing prescriptions as early as this Saturday. The therapy aims to manage the immune system's attack on the tissues and muscles behind the eyes, a process that often results in severe symptoms such as bulging, chronic dryness, and double vision.

By including data for both active and chronic presentations of the disease in its official labeling, Lumvoa establishes a broader clinical reach than previous standards of care. Investors and medical professionals can review the specific details of the rollout and clinical expectations during a scheduled conference call and webcast on June 29 at 8 a.m. ET.